To investigate the clinical relevance of CAV1, CD47 and FLNC we analysed the transcriptomic data from 67 HCC cases in the Biostorm cohort of the Storm trial, a phase 3 clinical study exploring sorafenib as an adjuvant therapy in liver cancer patients who had previously had local ablation surgery. This evidence concerns the gene CAV1 and liver cancer.